Neutrophil elastase and obliterative bronchiolitis

Authors

  • J.P. Scott,

    1. Division of Thoracic Diseases, East 18th Floor, Mayo Clinic, 200 1st Street SW, Rochester, Minnesota 55905, USA
    Search for more papers by this author
  • D.W. Holt,

    1. Division of Thoracic Diseases, East 18th Floor, Mayo Clinic, 200 1st Street SW, Rochester, Minnesota 55905, USA
    Search for more papers by this author
  • J. Wallwork

    Corresponding author
    1. Division of Thoracic Diseases, East 18th Floor, Mayo Clinic, 200 1st Street SW, Rochester, Minnesota 55905, USA
      Dept. of Cardiothoracic Surgery, Papworth Hospital, Cambridgeshire, UK
    Search for more papers by this author

Dept. of Cardiothoracic Surgery, Papworth Hospital, Cambridgeshire, UK

Abstract

Abstract Bronchoalveolar lavage levels of elastase were assayed to determine the timing and magnitude of elevations in elastase relative to both fibrosis, as indicated by hyaluronate (HA) levels, and decline in FEV, characteristic of the clinical syndrome of obliterative bronchiolitis (OB). Samples were collected from 48 heart-lung or single lung transplant recipients. Regression analysis was performed and demonstrated that high levels of elastase occurred with active decline in lung function and in association with high levels of HA. This study suggested that intense neutrophil elastase release occurs concurrent with the development of OB and may contribute to the destruction of bronchiolar architecture.

Ancillary